Latest Hotspot

Immorna Biotherapeutics' JCXH-211 Receives FDA IND Approval for Phase 1/2 Solid Tumor Trial

10 July 2024
3 min read

Immorna Biotherapeutics, Inc., a clinical-stage biotech firm focused on the development of both self-replicating and traditional mRNA-based therapies and vaccines, revealed that the U.S. Food and Drug Administration has approved its investigational new drug application for JCXH-211 intravenous. This innovative, first-of-its-kind self-replicating mRNA encodes the modified human interleukin (IL)-12 protein.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The IND clearance permits Immorna to commence a Phase 1/2, multi-center, open-label, dose escalation and expansion trial of JCXH-211, which will be administered intravenously to patients with malignant solid tumors. The objectives of the trial are to evaluate safety and tolerance, establish the recommended Phase 2 dose (RP2D) for JCXH-211 IV when combined with a checkpoint inhibitor, and preliminarily assess the efficacy of the combination at the RP2D.

“Grounded on data from our preclinical studies and the clinical data from our JCXH-211 intratumoral administration trial, along with the candidate drug’s mechanism of action, we are optimistic that JCXH-211 IV, in combination with a checkpoint inhibitor, has the potential to synergistically enhance anti-tumor effects. We eagerly anticipate collaborating with investigators and patients to deliver this potentially groundbreaking therapy to those in urgent need of new and effective treatments,” stated NgocDiep Le, M.D., Ph.D., President and Global Chief Medical Officer of Immorna.

JCXH-211 is a pioneering lipid nanoparticle encapsulated srRNA, developed using Immorna’s proprietary technology, that encodes the engineered human IL-12 protein. In various preclinical animal and patient-derived xenograft models, the RNA replicon-induced anti-viral innate response combined with the IL-12 stimulated potent anti-cancer immunity endowed JCXH-211 with superior tumor-eradicating capabilities, surpassing similar preclinical candidates using conventional mRNA.

IL-12 is a naturally occurring cytokine integral to the body’s immune response against cancer. Despite demonstrating strong antitumor activity in preclinical trials, recombinant IL-12 protein treatments at tolerable doses in humans have not yielded clinical benefits. The primary obstacle for IL-12 protein treatments is the non-overlapping tolerability and therapeutic windows. Recombinant IL-12 is unstable in vivo and possesses a very short half-life, with frequent intravenous administration posing significant toxicity challenges.

Due to the intrinsic features of our srRNA technology, JCXH-211 IV enables prolonged expression of IL-12 primarily in tumor tissues, rather than normal tissues, thus modulating the tumor microenvironment and activating antitumor immune responses while minimizing systemic toxicity. JCXH-211 IV demonstrated an excellent safety profile in nonclinical studies conducted on rodents and non-human primates. Should it succeed, JCXH-211 IV could become a lifesaving and easily accessible treatment for cancer patients who have not responded to or are resistant to existing therapies.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of July 10, 2024, there are 108 investigational drugs for the IL-12 target, including 134 indications, 150 R&D institutions involved, with related clinical trials reaching 290, and as many as 44510 patents.

JCXH-211 represents an innovative mRNA vaccine targeting IL-12 with potential applications in the treatment of neoplasms, skin and musculoskeletal diseases, nervous system diseases, and other conditions. The drug is currently in Phase 1 of clinical development, and further research and clinical trials will be needed to determine its safety and efficacy in treating the indicated conditions.

图形用户界面, 文本, 应用程序

描述已自动生成

Is Casimersen approved by the FDA?
Drug Insights
3 min read
Is Casimersen approved by the FDA?
10 July 2024
Casimersen was approved by the U.S. Food and Drug Administration (FDA) on February 25, 2021.
Read →
European Union Approval for Mirum Pharmaceuticals’ LIVMARLI to Treat PFIC Patients
Latest Hotspot
3 min read
European Union Approval for Mirum Pharmaceuticals’ LIVMARLI to Treat PFIC Patients
10 July 2024
Mirum Pharmaceuticals, Inc. revealed that the European Commission has approved the marketing authorization for LIVMARLI® (maralixibat) oral solution
Read →
Is Trilaciclib approved by the FDA?
Drug Insights
3 min read
Is Trilaciclib approved by the FDA?
10 July 2024
Trilaciclib was approved by the U.S. Food and Drug Administration (FDA) on February 12, 2021.
Read →
The European Union has approved Dupixent® (dupilumab) as the first targeted therapy for COPD patients
Latest Hotspot
4 min read
The European Union has approved Dupixent® (dupilumab) as the first targeted therapy for COPD patients
10 July 2024
Regeneron Pharmaceuticals, Inc. and Sanofi announced today that the European Commission has granted approval for Dupixent (dupilumab) as an additional maintenance therapy for adults with uncontrolled chronic obstructive pulmonary disease with elevated blood eosinophils.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.